Exosens (EXENS) Aandelenoverzicht
Exosens houdt zich bezig met de ontwikkeling, productie en verkoop van elektro-optische technologieën op het gebied van versterking, detectie en beeldvorming in Frankrijk, de rest van Europa, Noord-Amerika, Azië, Oceanië en Afrika. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
EXENS Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Exosens Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €61.75 |
| 52 Week Hoogtepunt | €74.00 |
| 52 Week Laag | €36.20 |
| Bèta | 0 |
| 1 maand verandering | 2.83% |
| 3 maanden verandering | -6.30% |
| 1 Jaar Verandering | 37.53% |
| 3 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 174.44% |
Recent nieuws en updates
Narratiefupdate • May 24
EXENS: Defense Contracts And Higher Future P E Assumptions Will Support Future Earnings Power
Analysts have raised their average price targets on Exosens to a range of €55 to €71, and your updated fair value narrative remains at €75. This change is supported by revised assumptions that include slightly higher revenue growth, a higher future P/E, and an updated discount rate.
Narratiefupdate • May 09
EXENS: Defense Backlog And Higher P E Range Will Shape Upside Outlook
Exosens' updated analyst price target has edged higher by about €0.30, with the adjustment supported by recent target increases from Berenberg, JPMorgan, Deutsche Bank and Citi. These changes reflect refreshed assumptions on growth, profitability and P/E multiples.Recent updates
Narratiefupdate • May 24
EXENS: Defense Contracts And Higher Future P E Assumptions Will Support Future Earnings Power
Analysts have raised their average price targets on Exosens to a range of €55 to €71, and your updated fair value narrative remains at €75. This change is supported by revised assumptions that include slightly higher revenue growth, a higher future P/E, and an updated discount rate.Narratiefupdate • May 09
EXENS: Defense Backlog And Higher P E Range Will Shape Upside Outlook
Exosens' updated analyst price target has edged higher by about €0.30, with the adjustment supported by recent target increases from Berenberg, JPMorgan, Deutsche Bank and Citi. These changes reflect refreshed assumptions on growth, profitability and P/E multiples.Narratiefupdate • Apr 24
EXENS: Defense Backlog And Rich P E Will Shape Balanced Outlook
Exosens' analyst price target has been lifted, with the fair value estimate moving by €2 to €66.83 as analysts broadly raise their targets into a future P/E of about 32.8x, citing updated views reflected in recent price target increases from multiple banks. Analyst Commentary Recent research points to a cluster of higher targets around the current fair value estimate, with price objectives now ranging from €55 to €71.Narratiefupdate • Apr 10
EXENS: Defense Contracts And Higher Future P E Assumptions Will Support Earnings Power
Exosens' updated analyst price target has shifted from €61.00 to €75.00. This reflects analysts' revised fair value views, supported by a series of recent target increases from major banks citing their latest assessments on growth, profitability and P/E assumptions.Narratiefupdate • Mar 27
EXENS: Defense Backlog And New Shareholder Support Will Shape Balanced Outlook
Exosens' analyst price targets have moved higher, with recent updates ranging from about €55 to €71 as analysts factor in their latest views on growth, margins and valuation multiples, while the model's fair value estimate remains steady at €64.83. Analyst Commentary Recent Street research on Exosens clusters around higher price targets in a relatively tight band, giving you a clearer sense of how the market is framing potential risk and reward.Narratiefupdate • Mar 12
EXENS: Defense Contracts And New Shareholder Support Will Underpin Measured Outlook
Exosens' analyst price target has been revised higher to €64.83 from €51.33, reflecting updated assumptions on revenue growth, profit margins, and future P/E in line with recent price target increases from several banks including JPMorgan, Deutsche Bank, Citi, and Berenberg. Analyst Commentary Recent research shows a cluster of higher price targets on Exosens, with JPMorgan at the upper end and several other banks setting targets in a similar range.
Narratiefupdate • Feb 22
EXENS: Future Defense Contracts Will Still Reveal Extended Overvaluation Risk
Analysts have nudged their price target on Exosens slightly higher to €39.06 from €38.30, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E, which together support a modest uplift in estimated fair value. What's in the News Theon International completed the acquisition of a 9.8% stake in Exosens for about €268.7 million at €54 per share, making Theon the second largest shareholder after Groupe HLD, following regulatory clearances and closing on January 7, 2026 (Key Developments).Narratiefupdate • Feb 07
EXENS: Defense Contracts And New Shareholder Support Will Strengthen Future Earnings Power
Analysts have maintained their price target for Exosens at €61.00. They cite only minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, which they view as offsetting one another.Narratiefupdate • Jan 24
EXENS: Long Term Defense Contracts Will Drive Future Earnings Power Higher
Analysts now set their fair value estimate for Exosens at $61.00, compared with the prior $60.00, citing adjusted assumptions around discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. What's in the News Theon International Plc completed the acquisition of a 9.8% stake in Exosens for approximately €268.7 million at €54 per share, becoming the second largest shareholder after Groupe HLD (M&A Transaction Closings).Narratiefupdate • Jan 10
EXENS: Future Defense Contracts Will Expose Overvaluation Risk Despite Extended Supply Agreement
Analysts have raised their price target on Exosens to about $38.30 from $33.50, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they see as better reflecting the company’s current outlook. What's in the News Theon International completed the acquisition of a 9.8% stake in Exosens from Invest Gamma, HLD Europe S.C.A. and Invest Prince Henri SCA for about €268.7 million at €54 per share.Narratiefupdate • Dec 26
EXENS: German Defense Contract Will Drive Earnings Power Higher
Analysts have raised their price target on Exosens from 50.50 dollars to 60.00 dollars, citing expectations for slightly faster revenue growth, modestly higher profit margins, and a richer future earnings multiple supported by a marginally lower discount rate. What's in the News Exosens and Theon International secured a landmark OCCAR contract to supply 100,000 Mikron binocular devices embedding 200,000 16mm tubes for the German Armed Forces and additional devices for Belgium, a deal valued at more than EUR 500 million and described as likely the largest night vision contract ever concluded globally (Key Developments).Narratiefupdate • Dec 12
EXENS: Extended Defense Contracts And Equity Stake Will Support Steady Outlook
Analysts have raised their price target on Exosens from approximately $49.67 to $51.33, citing a modestly lower discount rate and slightly higher expected future valuation multiples, despite marginally softer revenue growth and profit margin assumptions. What's in the News Exosens and Theon International extended their long term commercial agreement for Image Intensifier Tubes by three years to cover potential deliveries through 2030, with Theon set to convert 2027 and 2028 options into firm orders and increase its annual purchase volumes (company announcement).Narratiefupdate • Nov 28
EXENS: Major Defense Contract Will Drive Demand Momentum Through 2028
Analysts have slightly adjusted their price target for Exosens, maintaining it at $49.67. The updated expectations reflect a marginal decrease in projected revenue growth, which is offset by a modest improvement in anticipated profit margins.Narratiefupdate • Nov 13
EXENS: Recent Stake Acquisition and Defense Contract Will Shape Outlook Through 2028
Analysts have raised their price target for Exosens from $48.67 to $49.67, citing improved revenue growth forecasts and a slightly lower discount rate as key factors behind the increase. What's in the News Theon International Plc entered into a definitive agreement to acquire a 9.8% stake in Exosens for approximately €270 million, making Theon the second largest shareholder upon completion.Narratiefupdate • Oct 30
EXENS: Defense Sector Demand And Shareholder Shift Will Shape Outlook
Analysts have raised their price target for Exosens from $47.56 to $48.67, citing incremental improvements in revenue growth, profit margins, and future earnings expectations. What's in the News Theon International Plc has entered into a definitive agreement to acquire a 9.8% stake in Exosens for approximately €270 million, which would make Theon the second largest shareholder, pending regulatory approval.Analyseartikel • Oct 27
Calculating The Intrinsic Value Of Exosens (EPA:EXENS)
Key Insights Exosens' estimated fair value is €53.11 based on 2 Stage Free Cash Flow to Equity Exosens' €47.50 share...Narratiefupdate • Oct 16
Rising NATO Spending Will Boost Night Vision And Advanced Sensing
Analysts have raised their price target for Exosens from $45.50 to $47.56, citing expectations of slightly stronger revenue growth and higher future valuation multiples. What's in the News Theon International Plc has agreed to acquire a 9.8% stake in Exosens for approximately €270 million, becoming the company's second largest shareholder.Analyseartikel • Sep 15
Exosens (EPA:EXENS) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narratiefupdate • Sep 10
Rising NATO Spending Will Boost Night Vision And Advanced Sensing
Despite a reduction in consensus revenue growth forecasts, the valuation multiple for Exosens SAS has increased, driving the analyst price target up from €42.57 to €45.50. What's in the News Exosens announces a share repurchase program of up to 240,000 shares, intended to cover performance share plans for employees, with an expiration date of October 31, 2025.Narratiefupdate • Aug 08
Rising NATO Spending Will Boost Night Vision And Advanced Sensing
With no significant changes in Exosens' discount rate or future P/E, the consensus analyst price target remained steady at €42.57. What's in the News Exosens announces a share repurchase program for up to 240,000 shares, with repurchased shares to be used for employee performance share plans and offer expiring on October 31, 2025.Analyseartikel • Aug 03
Exosens (EPA:EXENS) Released Earnings Last Week And Analysts Lifted Their Price Target To €41.21
It's been a good week for Exosens ( EPA:EXENS ) shareholders, because the company has just released its latest...Analyseartikel • Jul 25
Exosens' (EPA:EXENS) Intrinsic Value Is Potentially 26% Above Its Share Price
Key Insights The projected fair value for Exosens is €50.06 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Jul 06
Exosens (EPA:EXENS) Might Have The Makings Of A Multi-Bagger
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Analyseartikel • Jun 13
Exosens (EPA:EXENS) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Nieuw narratief • Jun 08
Elevated Defense Spending Will Challenge Overvaluation And Unleash Upside
Growth and profitability expectations rely on sustained global defense spending, rapid demand capture, and seamless operational execution, making them vulnerable to defense cycle shifts and integratiAnalyseartikel • May 29
Market Participants Recognise Exosens' (EPA:EXENS) Revenues Pushing Shares 27% Higher
Exosens ( EPA:EXENS ) shares have continued their recent momentum with a 27% gain in the last month alone. Longer-term...Analyseartikel • Mar 06
€31.58 - That's What Analysts Think Exosens (EPA:EXENS) Is Worth After These Results
The investors in Exosens 's ( EPA:EXENS ) will be rubbing their hands together with glee today, after the share price...Analyseartikel • Mar 05
Optimistic Investors Push Exosens (EPA:EXENS) Shares Up 37% But Growth Is Lacking
Exosens ( EPA:EXENS ) shares have continued their recent momentum with a 37% gain in the last month alone. Longer-term...Analyseartikel • Feb 14
Exosens' (EPA:EXENS) Intrinsic Value Is Potentially 96% Above Its Share Price
Key Insights The projected fair value for Exosens is €42.30 based on 2 Stage Free Cash Flow to Equity Exosens' €21.56...Rendement voor aandeelhouders
| EXENS | FR Aerospace & Defense | FR Markt | |
|---|---|---|---|
| 7D | -9.4% | -1.8% | -0.08% |
| 1Y | 37.5% | 5.3% | 1.8% |
Rendement versus industrie: EXENS overtrof de French Aerospace & Defense industrie, die het afgelopen jaar een rendement 5.3 % opleverde.
Rendement versus markt: EXENS overtrof de French markt, die het afgelopen jaar een rendement opleverde van 1.8 %.
Prijsvolatiliteit
| EXENS volatility | |
|---|---|
| EXENS Average Weekly Movement | 6.8% |
| Aerospace & Defense Industry Average Movement | 6.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.8% |
Stabiele aandelenkoers: EXENS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de French markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van EXENS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1937 | 1,499 | Jerome Cerisier | www.exosens.com |
Exosens houdt zich bezig met de ontwikkeling, productie en verkoop van elektro-optische technologieën op het gebied van versterking, detectie en beeldvorming in Frankrijk, de rest van Europa, Noord-Amerika, Azië, Oceanië en Afrika. Het bedrijf biedt beeldversterkerbuizen, ultraviolet-, kort- en langgolvig infrarood-, zichtbaar - nabij infrarood- en middengolvig infraroodcamera's, evenals apparatuur voor verbeterd zicht, producten voor ionen- en elektronendetectie, scintillatie en detectie van enkele fotonen, röntgencomponenten, neutronische beeldverwerkingsproducten en beeldversterkers voor wetenschappelijke toepassingen, en gamma- en neutronendetectoren en mineraalgeïsoleerde uitbreidingen. Het bedrijf levert ook stroombuizen en microgolftoestellen en oplossingen voor detectie van methaan in de lucht.
Exosens Samenvatting
| EXENS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €3.13b |
| Inkomsten(TTM) | €70.19m |
| Inkomsten(TTM) | €468.19m |
44.6x
Koers/Winstverhouding6.7x
P/S-verhoudingIs EXENS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| EXENS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €468.19m |
| Kosten van inkomsten | €186.99m |
| Brutowinst | €281.19m |
| Overige uitgaven | €211.00m |
| Inkomsten | €70.19m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Jul 28, 2026
| Winst per aandeel (EPS) | 1.38 |
| Brutomarge | 60.06% |
| Nettowinstmarge | 14.99% |
| Schuld/Eigen Vermogen Verhouding | 56.1% |
Hoe presteerde EXENS op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.5%
Huidig dividendrendement22%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/07 17:25 |
| Aandelenkoers aan het einde van de dag | 2026/06/05 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Exosens wordt gevolgd door 15 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Amelie Dueckelmann-Dublany | Berenberg |
| Aleksander Peterc | Bernstein |
| Laurent Gelebart | BNP Paribas |